康华生物(300841) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 311,367,042.84, representing an increase of 11.96% compared to CNY 278,114,028.88 in the same period last year[16] - Net profit attributable to shareholders for Q1 2024 was CNY 149,466,993.99, a 42.09% increase from CNY 105,190,616.53 year-on-year[16] - The basic earnings per share for Q1 2024 was CNY 1.1204, reflecting a 42.45% increase from CNY 0.7865 in the same period last year[16] - The diluted earnings per share also increased by 42.49% to CNY 1.1204 from CNY 0.7863 year-on-year[16] - Operating profit reached approximately $172.15 million, up 47.2% from $117.04 million year-over-year[45] - The company reported a significant increase in other income, which rose to approximately $491.51 thousand from $261.01 thousand, marking an increase of 88.4%[45] - Comprehensive income for the period was ¥149,466,993.99, compared to ¥105,190,616.53 in the previous period[57] Cash Flow and Assets - The net cash flow from operating activities surged to CNY 98,589,924.72, marking a significant increase of 483.65% compared to CNY 16,892,087.59 in the previous year[10] - The company's cash and cash equivalents at the end of Q1 2024 were RMB 1,007,828,965.84, slightly down from RMB 1,039,366,021.16 at the beginning of the quarter[41] - The total cash and cash equivalents at the end of the period stood at approximately $1.01 billion, compared to $614.97 million at the end of the previous period[49] - The company's total assets at the end of Q1 2024 were CNY 4,201,733,978.11, a slight decrease of 0.18% from CNY 4,209,268,312.24 at the end of the previous year[16] - Current assets totaled ¥2,644,447,623.68, a slight decrease from ¥2,656,897,485.87[56] Liabilities and Equity - The equity attributable to shareholders increased by 2.48% to CNY 3,601,086,123.96 from CNY 3,514,051,747.38 at the end of the previous year[16] - The total liabilities decreased to RMB 600,647,854.15 from RMB 695,216,564.86, reflecting a reduction in financial obligations[44] - The company repurchased shares, resulting in an increase in treasury stock to CNY 185,530,157.25, a rise of 50.72% from CNY 123,097,539.84[9] Operating Costs and Expenses - Total operating costs decreased to RMB 134,855,630.79, down 19.0% from RMB 166,597,332.57 in the same period last year[44] - The company reported a significant reduction in operating costs, which may enhance profitability in upcoming quarters[44] - Research and development expenses decreased to approximately $25.83 million from $48.66 million, indicating a reduction of 46.8%[45] - R&D expenses decreased by 46.92% to ¥25,825,264.01 due to reduced phase investments in projects[54] - The company incurred financial expenses of approximately -$2.20 million, compared to -$1.72 million in the previous period, reflecting an increase in interest expenses[45] Shareholder Information - The number of ordinary shareholders is 16,305,468, with the top ten shareholders holding a significant portion of the shares[21] Future Plans and Commitments - The company plans to continue expanding its market presence and invest in new product development to drive future growth[44] - The company plans to continue expanding its market presence and investing in new product development, particularly in the field of vaccines[52] - The company is committed to adhering to new accounting standards starting from 2024, which may impact future financial reporting[32] Other Notable Changes - The company reported a decrease in contract liabilities by 37.56% to CNY 184,511.39, down from CNY 295,511.18[9] - The company experienced a significant reduction in employee compensation payable, decreasing by 58.87% to CNY 14,370,460.44 from CNY 34,942,933.81[9] - The company reported a significant reduction in impairment losses on materials, leading to a 151.32% decrease in asset impairment losses[54] - Fair value changes in profit and loss dropped by 96.00% to ¥521,701.06, resulting from changes in the fair value of equity investments[54] - Income tax expenses rose by 93.85% to ¥22,677,282.89, driven by an increase in total profit[54] Audit Status - The first quarter report is unaudited, indicating that the figures may be subject to change upon final review[50]